CLPTM1L expression predicts recurrence of patients with intermediate‑ and high‑risk stage IB‑IIB cervical cancer undergoing radical hysterectomy followed by TP as adjuvant chemotherapy

According to the National Comprehensive Cancer Network clinical practice guidelines of cervical cancer, concurrent chemoradiotherapy or radiotherapy is suggested for patients who receive radical hysterectomy and have intermediate‑ high‑risk cancer. However, adjuvant chemotherapy has been increasingly chosen given adverse events associated with increase in evidence regarding efficacy chemotherapy. Given that not a standard treatment at present, if recurrence after could be predicted, it would assist decision gynecological oncologists selecting which therapy (chemotherapy radiation therapy) use. Cleft lip palate transmembrane protein 1‑like (CLPTM1L; also known as cisplatin resistance‑related 9) apoptotic mechanisms related proliferation tumor cells resistance against In present study, association between CLPTM1L expression stage IB‑IIB cancer undergoing followed by paclitaxel (TP) was determined. Patients were divided into two groups: Recurrence group no‑recurrence group. examined using immunohistochemistry paraffin‑embedded sections weighted scores. Regarding characteristics patients, histology non‑squamous cell carcinoma, lymph node metastasis parametrium invasion more common compared non‑recurrence group, significantly higher than Next, low high‑expression groups based on score cut‑off value 6. high exhibited rate (37.5 vs. 5.1%) had worse overall survival. Multivariate analysis revealed independently recurrence. vitro analysis, small interfering RNA‑mediated knockdown enhanced sensitivity cisplatin. conclusion, study may predictive biomarker TP